Gene

ABCC3

ATP binding cassette subfamily C member 3

Explore in graph →CI-GENE-00000075HGNC:54 ENSG00000108846 NCBI 8714 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABCC3 Amplification1
Monomethyl Auristatin E + PaclitaxelSubstitutes	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	3	accepted	EID951 44 cell lines and 145 patient samples were utilized in various aspects of this study. 31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE). Genome wide… (full text at CIViC) PMID 18593940 · O'Brien et al., 2008 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (12)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved12 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Prostate Cancer MDA PCa PDX (MD Anderson, Clin Cancer Res 2024) prad_msk_mdanderson_2023	unmapped	Ssm	9	44	20.5%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
· Cancer Res · 2008 · PMID 18593940 · validated civic_curation pubmed